These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29432282)

  • 61. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
    Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
    Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
    Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
    Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
    Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
    Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
    Iwasa S; Yamada Y; Heike Y; Shoji H; Honma Y; Komatsu N; Matsueda S; Yamada A; Morita M; Yamaguchi R; Tanaka N; Kawahara A; Kage M; Shichijo S; Sasada T; Itoh K
    Cancer Sci; 2016 May; 107(5):590-600. PubMed ID: 26920496
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Noguchi M; Uemura H; Naito S; Akaza H; Yamada A; Itoh K
    Prostate; 2011 Apr; 71(5):470-9. PubMed ID: 20878951
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.
    Müller S; Agnihotri S; Shoger KE; Myers MI; Smith N; Chaparala S; Villanueva CR; Chattopadhyay A; Lee AV; Butterfield LH; Diaz A; Okada H; Pollack IF; Kohanbash G
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618666
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
    Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
    Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.
    Obara W; Ohsawa R; Kanehira M; Takata R; Tsunoda T; Yoshida K; Takeda K; Katagiri T; Nakamura Y; Fujioka T
    Jpn J Clin Oncol; 2012 Jul; 42(7):591-600. PubMed ID: 22636067
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
    Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
    Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.
    Kim S; Chung HW; Kong HY; Lim JB
    Yonsei Med J; 2017 Jan; 58(1):43-50. PubMed ID: 27873494
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
    Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
    Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice.
    Sultan H; Kumai T; Nagato T; Wu J; Salazar AM; Celis E
    Cancer Immunol Immunother; 2019 Mar; 68(3):455-466. PubMed ID: 30604041
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peptide vaccines for hepatocellular carcinoma.
    Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
    Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
    Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
    Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
    Cusi MG; Botta C; Pastina P; Rossetti MG; Dreassi E; Guidelli GM; Fioravanti A; Martino EC; Gandolfo C; Pagliuchi M; Basile A; Carbone SF; Ricci V; Micheli L; Tassone P; Tagliaferri P; Pirtoli L; Correale P
    Cancer Immunol Immunother; 2015 Sep; 64(9):1159-73. PubMed ID: 26031574
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ohno I; Mitsunaga S; Kondo S; Ueno H; Morizane C; Gemmoto K; Suna H; Ushida Y; Furuse J
    Immunotherapy; 2021 Apr; 13(5):371-385. PubMed ID: 33525928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.